$131.72
2.71% yesterday
NYSE, Oct 01, 10:05 pm CET
ISIN
US66987V1098
Symbol
NVS

Novartis ADR Stock News

Neutral
PRNewsWire
one day ago
Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring 1 1.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines 2,3 Remibrutinib al...
Positive
Reuters
one day ago
The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday.
Neutral
GlobeNewsWire
one day ago
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring 1   1.7 million people in US live with CSU; more than half remain symptomatic despite increasin...
Positive
WSJ
3 days ago
The company is the latest pharma giant to move on price-cutting ahead of the Trump administration's deadline.
Neutral
GlobeNewsWire
3 days ago
Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescribed Cosentyx® (secukinumab) the option to purchase it at a 55% discount off the list price. Cosentyx, Novartis top selling product in the US, is a biologic that is FDA-approved for the treatment o...
Neutral
GlobeNewsWire
3 days ago
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, i...
Negative
Investors Business Daily
5 days ago
President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.
Neutral
GlobeNewsWire
6 days ago
Basel, September 26, 2025 – Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2025).
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today